Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2025)

Innate Pharma has reported Long-Term Debt Repayments for 7 years, with the latest figure at -$10.4 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Debt Repayments fell 8.63% year-over-year to -$10.4 million; the trailing twelve-month figure through Dec 2025 stood at -$22.5 million (down 62.47% YoY), and the FY2025 full-year result was -$10.4 million, down 8.63% from the prior year.
• Long-Term Debt Repayments for Q4 2025 stood at -$10.4 million, down from -$9.5 million in the prior quarter.
• The five-year high for Long-Term Debt Repayments was -$1.0 million in Q2 2022, with the low at -$10.4 million in Q4 2025.
• Historically, Long-Term Debt Repayments has averaged -$3.9 million across 5 years, with a median of -$2.2 million in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Debt Repayments advanced 24.68% — and 2024, when it plunged 275.9%.
• Innate Pharma's Long-Term Debt Repayments stood at -$2.4 million in 2021, then grew by 12.67% to -$2.1 million in 2022, then fell by 22.9% to -$2.5 million in 2023, then tumbled by 275.9% to -$9.5 million in 2024, then dropped by 8.63% to -$10.4 million in 2025.
• The last three Long-Term Debt Repayments figures came in at -$10.4 million (Q4 2025), -$9.5 million (Q4 2024), and -$2.5 million (Q4 2023), per Business Quant data.